Drugs Xagena
Peroxisome proliferatoractivated receptors ( PPARs ) are ligand-activated nuclear transcription factors that modulate expression of a large number of genes. In the United States, therapeutic agent ...
Takeda Pharmaceuticals, in according to FDA ( Food and Drug Administration ) has informed healthcare providers about recent safety data concerning Pioglitazone-containing products, i.e., Actos, ActoPl ...
The FDA ( Food and Drug Administration ) is aware of a potential safety issue related to Avandia ( Rosiglitazone ), a drug approved to treat type 2 diabetes. Safety data from controlled clinical tria ...
Novartis has provided a safety update to European regulators of pooled data showing numerically less frequent liver enzyme elevations in patients who took either 50 mg per day or 50 mg twice daily of ...
The FDA ( Food and Drug Administration ) announced manufacturers, GlaxoSmithKline ( GSK ) and Takeda, of glitazones approved to treat type 2 diabetes, have agreed to add a stronger warning on the risk ...
Rosiglitazone (Avandia, Avandamet ) and Pioglitazone ( Actos, Competact ) are treatments for patients with type 2 diabetes and belong to a class of drugs called thiazolidinediones ( also called glita ...
Thiazolidinediones include Rosiglitazone ( Avandia and Avandamet ) and Pioglitazone ( Actos ). These medicines act to increase insulin sensitivity and are widely prescribed to treat type II diabetes m ...
Long-term use of glitazones, oral diabetic drugs, doubles the risk of fractures in women with type 2 diabetes. The findings are published in the Canadian Medical Association Journal ( CMAJ ). In abso ...
Older adults who take Rosiglitazone ( Avandia ), a diabetes medication, appear to have a higher risk of death and heart failure than those taking the related medication Pioglitazone ( Actos ). In 1 ...
On September 23, 2010, the FDA ( Food and Drug Administration ) announced that it would restrict access to Rosiglitazone ( Avandia ) through use of a Risk Evaluation and Mitigation Strategy, or REMS.U ...
The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Onglyza ( Saxa ...
The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of a marketing authorisation for Incresync, 12.5 mg / 45 mg, 12.5 mg / 30 mg, 25 m ...
The FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) tablets, used with diet and exercise, to improve glycemic control in adults with type 2 diabetes.Type 2 diabetes is the ...
Empagliflozin is an oral selective SGLT-2 inhibitor that acts by blocking the reabsorption of glucose in the proximal tubules in the kidneys, and promotes excretion of excess glucose in the urine. ...
